FDA-cleared profile

uAngio AVIVA CX

Shanghai United Imaging Healthcare Co.,Ltd.

uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
uAngio AVIVA CX provides image guidance for diagnostic, interventional, and surgical procedures, including cardiac, neuro, vascular, nonvascular, rotational angiography, and whole-body radiographic or fluoroscopic procedures.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Trained radiologists, interventional clinicians, surgeons, and other qualified healthcare professionals who operate angiographic X-ray systems.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Diagnostic and interventional angiography suites, catheterization laboratories, operating rooms, and other procedure settings.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Acquires, displays, processes, stores, and communicates angiographic and fluoroscopic images for procedural guidance.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Patient registration and administrative information plus X-ray angiographic or fluoroscopic acquisition from the C-arm, detector, generator, and associated system components.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
2D and 3D displayed or postprocessed images, imported or archived studies, procedural views, and uSpace or uLingo-assisted system interactions.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243376
FDA source Exact FDA submission Checked 2026-08-31
Modality
Fluoroscopy/Angiography
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Whole body; cardiac, neuro, vascular and non-vascular anatomy
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-04-28
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA material describes patient registration, image acquisition, 2D/3D viewing and postprocessing, import, archiving, filming, and the uSpace camera and uLingo voice-control functions.
FDA source Exact FDA submission Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Deployment and data flow
The FDA material describes a physical angiographic X-ray system with C-arm, table, generator, tube, detector, monitors, and control modules; current room configuration, service, security, and interoperability remain unverified.
FDA source Exact FDA submission Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only Trained radiologists, interventional clinicians, surgeons, and other qualified healthcare professionals who operate angiographic X-ray systems should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor K243376 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.
FDA source Exact FDA submission Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K243376 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA material describes a physical angiographic X-ray system with C-arm, table, generator, tube, detector, monitors, and control modules; current room configuration, service, security, and interoperability remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes patient registration, image acquisition, 2D/3D viewing and postprocessing, import, archiving, filming, and the uSpace camera and uLingo voice-control functions.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The supported procedures, anatomy, patient table, radiation, detector, tube, and system configuration limits apply; clinicians control acquisition and radiation and retain responsibility for diagnosis and intervention.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K243376 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The K243376 FDA decision material supports the described angiographic system functions and nonclinical standards testing; it does not provide an AI algorithm performance endpoint or establish clinical outcomes.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K243376 FDA evidence package for uAngio AVIVA CX

FDA 510(k) system verification, validation, and applicable medical electrical and imaging standards testing. · The system components, supported angiographic procedures, and image-guidance functions described in the exact FDA material.

exact submission · Tested version: uAngio AVIVA CX configuration described in K243376 · Sponsor or vendor study

K243376

No product-specific AI clinical performance endpoint is promoted from this decision material.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243376 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

The discovery snapshot contains no PubMed or ClinicalTrials.gov candidates for K243376; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K252099

Trinias

Shimadzu Corporation

Trinias is an interventional fluoroscopic X-ray system for diagnostic and interventional angiography, including cardiac, neurovascular, abdominal, peripheral, rotational,...

Modality
Fluoroscopy/Angiography
Anatomy
Heart, neurovascular, abdominal, peripheral vessels, and whole body
Decision
2026-03-24
FDA-cleared K253614

EchoNavigator R5.0

Philips Medical Systems Nederland B.V.

EchoNavigator R5.0 supports an interventionalist or surgeon during cardiovascular treatment by combining live X-ray and live echocardiographic information.

Modality
Fluoroscopy/Angiography
Anatomy
Heart and cardiovascular structures
Decision
2026-03-17
FDA-cleared K252500

CARA System

Cara Medical, Ltd.

CARA assists adult structural-heart and conduction-system procedure planning by segmenting preprocedural CT, visualizing cardiac chambers and conduction landmarks, and overlaying...

Modality
Fluoroscopy/Angiography
Anatomy
Heart/Cardiovascular
Decision
2026-02-20